These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23415374)

  • 21. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
    Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
    Ludwig AH; Bujko M; Bidzinski M; KupryjaƄczyk J
    Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant expression of the CHFR prophase checkpoint gene in human B-cell non-Hodgkin lymphoma.
    Song A; Ye J; Zhang K; Yu H; Gao Y; Wang H; Sun L; Xing X; Yang K; Zhao M
    Leuk Res; 2015 May; 39(5):536-43. PubMed ID: 25798877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.
    Zhu J; Cai L; Yang H; Wen Y; Wang J; Rong T; Shao J; Zhang L
    Thorac Cancer; 2014 Sep; 5(5):411-6. PubMed ID: 26767032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant methylation of the CHFR gene in digestive tract cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(3A):1791-5. PubMed ID: 16827108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients.
    Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D
    Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
    Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
    Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of CHFR in human tumors.
    Toyota M; Sasaki Y; Satoh A; Ogi K; Kikuchi T; Suzuki H; Mita H; Tanaka N; Itoh F; Issa JP; Jair KW; Schuebel KE; Imai K; Tokino T
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7818-23. PubMed ID: 12810945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.
    Brodie SA; Li G; Brandes JC
    Respir Med; 2015 Jan; 109(1):131-6. PubMed ID: 25477232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
    Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
    Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes.
    Takeshita M; Koga T; Takayama K; Kouso H; Nishimura-Ikeda Y; Yoshino I; Maehara Y; Nakanishi Y; Sueishi K
    Int J Cancer; 2008 Oct; 123(7):1623-30. PubMed ID: 18623126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study of mRNA expression level and hypermethylation of CHFR promoter in the laryngeal squamous cell carcinoma tissue].
    He L; Ji W; Yang J; Zhao X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 24(15):673-7. PubMed ID: 20942233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Sato S; Miyazaki K
    J Gastroenterol; 2006 Feb; 41(2):133-9. PubMed ID: 16568372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.